Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in Experimental Diabetic Retinopathy

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2016 Mar 8

PMID 26949291

Citations 24

Authors

S Rossi

R Maisto

C Gesualdo

M C Trotta

F Ferraraccio

M K Kaneva

S J Getting

E Surace

F Testa

F Simonelli

P Grieco

F Merlino

M Perretti

M DAmico

C Di Filippo

Affiliations

Soon will be listed here.

Abstract

We hypothesize that melanocortin receptors (MC) could activate tissue protective circuit in a model of streptozotocin- (STZ-) induced diabetic retinopathy (DR) in mice. At 12-16 weeks after diabetes induction, fluorescein angiography (FAG) revealed an approximate incidence of 80% microvascular changes, typical of DR, in the animals, without signs of vascular leakage. Occludin progressively decreased in the retina of mice developing retinopathy. qPCR of murine retina revealed expression of two MC receptors, Mc1r and Mc5r. The intravitreal injection (5 μL) of the selective MC1 small molecule agonist BMS-470539 (33 μmol) and the MC5 peptidomimetic agonist PG-901 (7.32 nM) elicited significant protection with regular course and caliber of retinal vessels, as quantified at weeks 12 and 16 after diabetes induction. Mouse retina homogenate settings indicated an augmented release of IL-1α, IL-1β, IL-6, MIP-1α, MIP-2α, MIP-3α, and VEGF from diabetic compared to nondiabetic mice. Application of PG20N or AGRP and MC5 and MC1 antagonist, respectively, augmented the release of cytokines, while the agonists BMS-470539 and PG-901 almost restored normal pattern of these mediators back to nondiabetic values. Similar changes were quantified with respect to Ki-67 staining. Finally, application of MC3-MC4 agonist/antagonists resulted to be inactive with respect to all parameters under assessment.

Citing Articles

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy.

Lazzara F, Conti F, Sasmal P, Alikunju S, Rossi S, Drago F Front Pharmacol. 2024; 15:1415846.

PMID: 38953109 PMC: 11215076. DOI: 10.3389/fphar.2024.1415846.

Alpha-Melanocyte-Stimulating Hormone Maintains Retinal Homeostasis after Ischemia/Reperfusion.

Ng T, Cho J, Zhao J, Gardiner J, Wang E, Leung E Biomolecules. 2024; 14(5).

PMID: 38785932 PMC: 11118772. DOI: 10.3390/biom14050525.

Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?.

Gravina A, Panarese I, Trotta M, DAmico M, Pellegrino R, Ferraraccio F World J Gastroenterol. 2024; 30(9):1132-1142.

PMID: 38577176 PMC: 10989484. DOI: 10.3748/wjg.v30.i9.1132.

Therapeutic Effects of Stimulating the Melanocortin Pathway in Regulating Ocular Inflammation and Cell Death.

Wang S, Kahale F, Naderi A, Surico P, Yin J, Dohlman T Biomolecules. 2024; 14(2).

PMID: 38397406 PMC: 10886905. DOI: 10.3390/biom14020169.

Therapeutic Potential of Fingolimod in Diabetes Mellitus and Its Chronic Complications.

Li J, Nan X, Ma Y, Wang Z, Fang H Diabetes Metab Syndr Obes. 2024; 17:507-516.

PMID: 38318451 PMC: 10840523. DOI: 10.2147/DMSO.S385016.

References

Lindqvist N, Napankangas U, Lindblom J, Hallbook F . Proopiomelanocortin and melanocortin receptors in the adult rat retino-tectal system and their regulation after optic nerve transection. Eur J Pharmacol. 2003; 482(1-3):85-94. DOI: 10.1016/j.ejphar.2003.10.011. View

White N, Sun W, Cleary P, Danis R, Davis M, Hainsworth D . Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008; 126(12):1707-15. PMC: 2663518. DOI: 10.1001/archopht.126.12.1707. View

Moller C, Raun K, Jacobsen M, Pedersen T, Holst B, Conde-Frieboes K . Characterization of murine melanocortin receptors mediating adipocyte lipolysis and examination of signalling pathways involved. Mol Cell Endocrinol. 2011; 341(1-2):9-17. DOI: 10.1016/j.mce.2011.03.010. View

Grabbe S, Bhardwaj R, Mahnke K, Simon M, Schwarz T, Luger T . alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol. 1996; 156(2):473-8. View

Di Filippo C, Rossi C, Ferraro B, Maisto R, De Angelis A, Ferraraccio F . Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome. Mediators Inflamm. 2014; 2014:972761. PMC: 4119687. DOI: 10.1155/2014/972761. View

Leoni G, Voisin M, Carlson K, Getting S, Nourshargh S, Perretti M . The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature. Br J Pharmacol. 2010; 160(1):171-80. PMC: 2860217. DOI: 10.1111/j.1476-5381.2010.00688.x. View

Ahmed T, Montero-Melendez T, Perretti M, Pitzalis C . Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. Int J Inflam. 2013; 2013:985815. PMC: 3664505. DOI: 10.1155/2013/985815. View

Zeng X, Ng Y, Ling E . Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000; 17(3):463-71. DOI: 10.1017/s0952523800173122. View

Cheng L, Cheng L, Bi H, Zhang Z, Yao J, Zhou X . Alpha-melanocyte stimulating hormone protects retinal pigment epithelium cells from oxidative stress through activation of melanocortin 1 receptor-Akt-mTOR signaling. Biochem Biophys Res Commun. 2013; 443(2):447-52. DOI: 10.1016/j.bbrc.2013.11.113. View

10.

Grassel S, Opolka A, Anders S, Straub R, Grifka J, Luger T . The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum. 2009; 60(10):3017-27. DOI: 10.1002/art.24846. View

11.

Montero-Melendez T . ACTH: The forgotten therapy. Semin Immunol. 2015; 27(3):216-26. DOI: 10.1016/j.smim.2015.02.003. View

12.

Slominski A, Wortsman J, Luger T, Paus R, Solomon S . Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000; 80(3):979-1020. DOI: 10.1152/physrev.2000.80.3.979. View

13.

STRAND F . New vistas for melanocortins. Finally, an explanation for their pleiotropic functions. Ann N Y Acad Sci. 2000; 897:1-16. DOI: 10.1111/j.1749-6632.1999.tb07874.x. View

14.

Davis M, Tsang T, Qiu Y, Dayrit J, Freij J, Huffnagle G . Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio. 2013; 4(3):e00264-13. PMC: 3684832. DOI: 10.1128/mBio.00264-13. View

15.

Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M . Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005; 139(3):476-81. DOI: 10.1016/j.ajo.2004.10.004. View

16.

Redondo P, Garcia-Foncillas J, Okroujnov I, Bandres E . Alpha-MSH regulates interleukin-10 expression by human keratinocytes. Arch Dermatol Res. 1998; 290(8):425-8. DOI: 10.1007/s004030050330. View

17.

Martin L, Catania A, Hiltz M, Lipton J . Neuropeptide alpha-MSH antagonizes IL-6- and TNF-induced fever. Peptides. 1991; 12(2):297-9. DOI: 10.1016/0196-9781(91)90015-h. View

18.

Brownlee M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54(6):1615-25. DOI: 10.2337/diabetes.54.6.1615. View

19.

Cui H, Hayasaka S, Zhang X, Chi Z, Hayasaka Y . Effect of alpha-melanocyte-stimulating hormone on interleukin 8 and monocyte chemotactic protein 1 expression in a human retinal pigment epithelial cell line. Ophthalmic Res. 2005; 37(5):279-88. DOI: 10.1159/000087699. View

20.

Edling A, Gomes D, Weeden T, Dzuris J, Stefano J, Pan C . Immunosuppressive activity of a novel peptide analog of α-melanocyte stimulating hormone (α-MSH) in experimental autoimmune uveitis. J Neuroimmunol. 2011; 236(1-2):1-9. DOI: 10.1016/j.jneuroim.2011.04.015. View